TECHNETIUM TC-99M APCITIDE - Generic Drug Details

What are the generic drug sources for technetium tc-99m apcitide and what is the scope of patent protection?

Technetium tc-99m apcitide is the generic ingredient in one branded drug marketed by Cis Bio Intl Sa and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for TECHNETIUM TC-99M APCITIDE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
DailyMed Link:	TECHNETIUM TC-99M APCITIDE at DailyMed

US Patents and Regulatory Information for TECHNETIUM TC-99M APCITIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cis Bio Intl Sa	ACUTECT	technetium tc-99m apcitide	INJECTABLE;INJECTION	020887-001	Sep 14, 1998		DISCN	No	No

Expired US Patents for TECHNETIUM TC-99M APCITIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cis Bio Intl Sa	ACUTECT	technetium tc-99m apcitide	INJECTABLE;INJECTION	020887-001	Sep 14, 1998	5,443,815
Cis Bio Intl Sa	ACUTECT	technetium tc-99m apcitide	INJECTABLE;INJECTION	020887-001	Sep 14, 1998	5,645,815
Cis Bio Intl Sa	ACUTECT	technetium tc-99m apcitide	INJECTABLE;INJECTION	020887-001	Sep 14, 1998	5,508,020

Technetium Tc-99m Apcitide Market Dynamics and Financial Trajectory

Last updated: September 8, 2026

Technetium Tc-99m apcitide, marketed in the United States as AcuTect, was a niche nuclear-medicine diagnostic agent for imaging suspected lower-extremity deep-vein thrombosis. Its commercial trajectory was limited by competition from duplex ultrasonography, changing clinical practice, reimbursement pressure, and the product’s dependence on technetium-99m supply. Public sources do not disclose product-level revenue, profitability, current sales, or a continuing commercial franchise. The available record supports a conclusion of historical market withdrawal or commercial discontinuation rather than an active growth market.

What is technetium Tc-99m apcitide used for?

Technetium Tc-99m apcitide is a radiolabeled synthetic peptide that binds to activated platelet glycoprotein IIb/IIIa receptors. The resulting radiopharmaceutical was developed for scintigraphic imaging of acute lower-extremity deep-vein thrombosis, or DVT.

AcuTect was administered intravenously after reconstitution and radiolabeling with technetium-99m. The product was designed to identify thrombi containing activated platelets rather than to image venous anatomy directly.

The clinical value proposition was strongest where conventional venography was undesirable or where an additional imaging modality was needed. The product’s practical limitations included:

• Dependence on a nuclear pharmacy or radiopharmacy workflow.
• Exposure to technetium-99m availability and generator logistics.
• More complicated administration than ultrasound.
• Limited applicability outside suspected acute lower-extremity DVT.
• Competition from an established, nonradioactive diagnostic pathway.

The FDA-approved indication did not create a broad therapeutic market. It addressed a narrow diagnostic use within a clinical area dominated by ultrasound.

When did AcuTect receive FDA approval?

The U.S. Food and Drug Administration approved technetium Tc-99m apcitide injection under the AcuTect brand in the late 1990s. FDA labeling identifies the product as a diagnostic radiopharmaceutical for imaging suspected acute lower-extremity DVT in patients with signs and symptoms of the condition.[1]

The product was associated with Diatide, Inc., a specialty radiopharmaceutical company that developed peptide-based imaging agents. Diatide was later acquired by Schering AG, which expanded its radiopharmaceutical portfolio through the acquisition.[2]

Item	Publicly documented position
Active ingredient	Technetium Tc-99m apcitide
Brand	AcuTect
Product type	Diagnostic radiopharmaceutical
Primary use	Imaging suspected acute lower-extremity DVT
Biological target	Activated platelet glycoprotein IIb/IIIa
Administration	Intravenous radiolabeled injection
Original developer	Diatide, Inc.
Later corporate association	Schering AG
Current commercial profile	No evidence of an active, scaled U.S. commercial franchise
Product-level revenue	Not publicly disclosed

What was the market size for technetium Tc-99m apcitide?

The addressable market was structurally small. Apacitide did not compete across the entire thrombosis market. It competed within the diagnostic imaging segment for suspected DVT, and then within the smaller subset of cases in which a nuclear-medicine test was selected over ultrasound or venography.

Duplex compression ultrasonography became the primary diagnostic tool for suspected lower-extremity DVT because it is noninvasive, widely available, less expensive, repeatable, and does not require radioactive materials. That competitive position constrained demand for AcuTect regardless of its imaging performance.

The product also faced demand concentration. Use depended on:

1. A patient presenting with suspected DVT.
2. A clinician selecting nuclear imaging.
3. A facility having radiopharmacy access.
4. Payers reimbursing the procedure and radiopharmaceutical.
5. The product being available through the supply chain.

That sequence created a narrow commercial funnel. Even if the underlying DVT diagnostic market was substantial, only a limited share was available to apcitide.

How did duplex ultrasound affect the commercial trajectory?

Duplex ultrasound was the principal substitute and the most important market constraint.

Ultrasound does not require radiotracer preparation, avoids radiation exposure, and is generally available in hospitals and outpatient imaging centers. Clinical guidelines and routine practice generally favored ultrasound as the first-line evaluation for suspected lower-extremity DVT.[3]

AcuTect’s differentiation was based on platelet-targeted imaging, but that distinction did not overcome the operational advantages of ultrasound. A radiopharmaceutical can have a biologically differentiated mechanism and still lose commercial relevance when its diagnostic workflow is slower, more expensive, or less accessible.

The market therefore had low switching incentives:

Commercial factor	AcuTect position	Ultrasound position
Radiation exposure	Yes	No
Radiopharmacy required	Yes	No
Hospital availability	Limited by nuclear-medicine infrastructure	Broad
Repeatability	More constrained	High
Diagnostic workflow	Nuclear imaging protocol	Established vascular imaging protocol
Reimbursement complexity	Higher	Lower
Role in standard DVT workup	Niche or adjunctive	First-line in most settings

What is the FDA regulatory status of technetium Tc-99m apcitide?

The product’s historical FDA approval is documented in labeling and drug databases. Public commercial databases do not establish a meaningful current U.S. market presence.

A distinction is required between FDA approval history and current commercial availability. A product may retain an approval record while no longer being actively marketed. FDA drug databases and labeling records should not be interpreted as evidence of current sales.

The FDA’s Discontinued Drug Product List can identify products discontinued for reasons that are not related to safety or effectiveness. A commercial discontinuation can result from weak demand, manufacturing economics, supply constraints, corporate portfolio decisions, or a combination of these factors.[4]

Public sources do not provide a current, product-specific revenue stream or operating forecast for AcuTect. The most supportable commercial assessment is that the product is no longer a material marketed radiopharmaceutical in the United States.

What patents protected technetium Tc-99m apcitide?

The commercial protection for apcitide was likely based on a combination of:

• Peptide composition patents.
• Radiolabeled peptide composition claims.
• Diagnostic method-of-use patents.
• Formulation and kit claims.
• Manufacturing and radiolabeling process claims.

The original development program involved Diatide and related corporate entities. Patent protection for a late-1990s diagnostic radiopharmaceutical would normally have been concentrated in patents filed during the 1980s and 1990s. Those patents would generally have reached their statutory expiration dates by the 2010s, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and jurisdiction-specific rules.

No active, commercially significant U.S. patent estate is publicly evident today for technetium Tc-99m apcitide as a marketed product. The likely practical conclusion is that patent exclusivity is no longer the primary barrier to entry.

Protection category	Historical relevance	Current commercial relevance
Apcitide peptide composition	High	Low
Tc-99m conjugate or radiolabeled composition	High	Low
DVT imaging method	Moderate to high	Low
Injectable kit formulation	Moderate	Low
Radiolabeling process	Moderate	Potentially relevant only to manufacturing
Trade secrets and know-how	Moderate	Could matter for reproducibility and quality control

When did technetium Tc-99m apcitide lose exclusivity?

The exact final expiration date of every patent associated with AcuTect cannot be established from the public commercial record alone. The product’s principal patent families were filed sufficiently early that any ordinary U.S. patent term would generally have expired years ago.

For products approved before the modern Hatch-Waxman framework matured, patent-term analysis can be complicated by:

• Pre-1995 patent terms based on grant date.
• Patent term adjustment.
• Patent-term extension.
• Continuations and divisionals.
• Foreign counterpart differences.
• Assignment changes after corporate acquisitions.

There is no clear evidence of a current Paragraph IV dispute directed to technetium Tc-99m apcitide. The absence of such litigation is consistent with a product that has limited commercial demand and no substantial branded revenue base.

What is the Orange Book status of AcuTect?

AcuTect’s current Orange Book position is not a meaningful source of commercial protection. The Orange Book is primarily relevant to approved drug products with current or economically relevant reference-listed-drug status and patent certifications.

For a discontinued diagnostic radiopharmaceutical, the critical questions are whether:

• The product remains listed as a reference product.
• The product has active patent information in the Orange Book.
• A generic applicant has an economic incentive to file an ANDA.
• The reference product is commercially available for substitution.

No major current Paragraph IV campaign or generic-launch program is publicly associated with technetium Tc-99m apcitide. That reflects the limited revenue opportunity and the operational requirements of radiopharmaceutical manufacturing and distribution.

Are there biosimilar or generic risks for technetium Tc-99m apcitide?

Biosimilar risk is not applicable. Technetium Tc-99m apcitide is a synthetic peptide radiopharmaceutical, not a biologic.

The relevant competitive risk would be a generic or alternative radiopharmaceutical. In practice, the stronger threat was not a conventional tablet-style generic launch. It was substitution by:

• Duplex ultrasound.
• Venography in selected cases.
• Other imaging protocols.
• Clinical decision rules combined with D-dimer testing.
• Alternative nuclear-medicine agents, where available.

A generic entrant would face several barriers despite the likely expiration of historical patents:

• Small and uncertain demand.
• Radiopharmaceutical manufacturing requirements.
• Short product shelf life.
• Technetium-99m supply dependence.
• Specialized distribution.
• Limited reimbursement upside.
• Need for validated sterile production and quality systems.

These barriers can deter entry even when formal patent protection has expired.

What manufacturing and supply-chain barriers affect the product?

Technetium Tc-99m apcitide depends on the wider molybdenum-99/technetium-99m supply chain. Technetium-99m is commonly obtained from generators and must be incorporated into a radiopharmaceutical under controlled conditions.

The product’s commercial economics are affected by:

• Generator availability.
• Radiopharmacy capacity.
• Production scheduling.
• Radioactive decay.
• Same-day or near-term use requirements.
• Sterile manufacturing compliance.
• Distribution radius.
• Hospital nuclear-medicine infrastructure.

Unlike a conventional small-molecule drug, inventory cannot be held for long periods without substantial loss of usable activity. That reduces the ability to smooth demand and increases the cost of serving low-volume sites.

A product with narrow utilization must achieve enough geographic density to support radiopharmacy operations. Apacitide’s limited clinical role made that difficult.

What financial trajectory did technetium Tc-99m apcitide have?

The product’s financial trajectory can be summarized in four stages:

Development and launch

Diatide developed apcitide within a broader specialty radiopharmaceutical portfolio. The commercial thesis was based on platelet-targeted imaging and a potential role in DVT evaluation.

Early commercialization

The product entered a market where the clinical need was real but the competing diagnostic pathway was already entrenched. Adoption was likely concentrated in selected hospitals and nuclear-medicine practices rather than broad outpatient use.

Demand compression

Ultrasound, reimbursement considerations, workflow complexity, and the narrow label reduced repeat use and limited account penetration. The product also lacked the prescription-driven revenue profile of a chronic medicine.

Commercial decline or discontinuation

The later corporate history and absence of visible current commercial activity indicate that AcuTect did not develop into a durable, high-revenue franchise. No public filings identify material standalone revenue, current sales growth, or a significant continuing contribution to the financial results of its corporate owners.

Financial metric	Public status
Annual AcuTect revenue	Not disclosed
Peak sales	Not publicly established
Gross margin	Not disclosed
Product-level operating profit	Not disclosed
Current sales force	No public evidence of a dedicated franchise
Current market share	No reliable public estimate
Licensing royalties	Not publicly disclosed
Current value of branded exclusivity	De minimis or unestablished

Any valuation based on historical peak sales would be speculative. The commercial asset value today is more likely tied to residual know-how, regulatory documentation, manufacturing capability, or portfolio optionality than to protected product revenue.

Which companies challenged or competed with AcuTect?

No major current Paragraph IV challenger is publicly identified. The principal competitive threat was modality substitution rather than a named generic manufacturer.

Relevant competitors included:

• Hospitals using duplex ultrasound.
• Providers using contrast venography in selected cases.
• Other nuclear-medicine imaging agents.
• Diagnostic laboratories using D-dimer testing within clinical algorithms.
• Manufacturers of ultrasound systems and vascular-imaging equipment.

The absence of a high-profile generic challenger does not indicate strong patent protection. It more likely indicates that the market was too small and operationally difficult to justify development costs.

How does apcitide compare with other DVT diagnostic approaches?

Attribute	Tc-99m apcitide	Duplex ultrasound	Contrast venography
Radiation	Yes	No	Limited fluoroscopic radiation
Invasiveness	Intravenous radiotracer	Noninvasive	Invasive contrast procedure
Availability	Nuclear-medicine dependent	Broad	More limited
Cost profile	Generally less favorable	Generally favorable	Less favorable
Primary clinical role	Niche imaging	Standard first-line approach	Selective or historical use
Commercial outlook	Discontinued or minimal	Established	Limited

Apcitide had technical differentiation but weak market power. Ultrasound had less specialized biology and much stronger delivery economics.

What generic launch scenarios exist?

A conventional generic launch scenario is unlikely to create a significant market event. Three scenarios are more plausible:

1. A radiopharmacy or specialty diagnostic company revives the product for a limited institutional market.
2. A manufacturer develops a substitute radiolabeled platelet-targeting agent with a clearer clinical or operational advantage.
3. The product remains commercially inactive because ultrasound continues to satisfy the core diagnostic need.

The third scenario is the strongest based on available commercial evidence. Patent expiry alone would not create sufficient demand.

How strong is the patent estate for technetium Tc-99m apcitide?

The historical patent estate may have been adequate to support development and early commercialization, but it is not a strong current market barrier.

Patent strength is low on a present-value basis for four reasons:

• The core filing period is several decades old.
• The product has no visible active commercial franchise.
• No major current litigation is identified.
• Clinical substitution is stronger than patent exclusivity.

The remaining barriers are primarily regulatory, manufacturing, supply-chain, and reimbursement barriers. Those barriers can protect a low-volume market from casual entry, but they do not support a premium valuation comparable to an active branded medicine.

Key Takeaways

• Technetium Tc-99m apcitide, marketed as AcuTect, was a specialized DVT imaging radiopharmaceutical.
• Its market was constrained by duplex ultrasound, the standard competing diagnostic pathway.
• Product-level revenue, peak sales, royalties, and current profitability are not publicly disclosed.
• No meaningful current Paragraph IV, biosimilar, or generic litigation profile is evident.
• Historical patent protection is likely expired or commercially immaterial.
• The principal barriers are radiopharmacy operations, technetium-99m supply, radioactive decay, manufacturing compliance, and limited demand.
• The product’s financial trajectory is consistent with niche launch, weak commercial scale, and eventual discontinuation or minimal market activity.
• Any current asset value would likely come from residual regulatory and manufacturing know-how rather than branded exclusivity.

FAQs

Is technetium Tc-99m apcitide still sold in the United States?

Public information does not establish a meaningful current U.S. commercial market for AcuTect. Its historical FDA approval should not be treated as evidence of active marketing.

Is AcuTect a biologic?

No. Technetium Tc-99m apcitide is a synthetic peptide radiopharmaceutical. Biosimilar rules do not apply.

What disease was AcuTect intended to diagnose?

AcuTect was intended to image suspected acute lower-extremity deep-vein thrombosis.

Could a generic manufacturer relaunch technetium Tc-99m apcitide?

A relaunch is technically possible, but the commercial case is weak because ultrasound is widely available and the product requires specialized radiopharmaceutical manufacturing and distribution.

Did ultrasound replace technetium Tc-99m apcitide?

Ultrasound was not a direct legal replacement, but it was the principal clinical and commercial substitute. Its lower operational burden and established role limited demand for apcitide.

References

1. U.S. Food and Drug Administration. (1998). AcuTect technetium Tc-99m apcitide injection prescribing information.
2. Schering AG. (2000). Annual report and corporate acquisition disclosures concerning Diatide, Inc.
3. American College of Chest Physicians. (2012). Antithrombotic therapy and prevention of thrombosis, 9th ed.: Diagnosis of DVT. Chest, 141(2 Suppl).
4. U.S. Food and Drug Administration. (n.d.). Discontinued drug product list. FDA.